Down Syndrome Clinical Trials Review Research Report for H2 2015

Nov 04, 2015, 07:30 ET from ReportsnReports

PUNE, India, November 4, 2015 /PRNewswire/ --

Down Syndrome Global Clinical Trials Review, H2, 2015 provides a global overview and top line data relating to the clinical trials on Down Syndrome. Complete report on spread across 68 pages, analyzing 10 companies and supported with 23 tables and 23 figures is now available at

This report provides top line data relating to the clinical trials on Down Syndrome including an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). Global Data Clinical Trial Reports are generated using Global Data's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

Clinical Trial Overview of Top Companies covered in this report are F. Hoffmann-La Roche Ltd., Eisai Co., Ltd., Transition Therapeutics Inc., Pfizer Inc., Johnson & Johnson, Effi-stat, Biomnis, Balance Therapeutics, Inc., Ascopharm Groupe Novasco and Allergan Plc. Order a copy of Down Syndrome Global Clinical Trials Review, H2, 2015 market research report at .

The report provides a snapshot of the global clinical trials landscape along with top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status and reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company. The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment, enrollment trends for the past five years and latest news for the past three months.

Another newly published market research titled Premenstrual Syndrome - Pipeline Review, H2 2015 provides comprehensive information on the therapeutic development for Premenstrual Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premenstrual Syndrome and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Premenstrual Syndrome Pipeline Review research report of 41 pages is available at .

Explore more reports on pharmaceuticals market at

About Us: is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Connect With Us on:  



Twitter: https: //

G+ / Google Plus:



Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441

SOURCE ReportsnReports